Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent.
diabetes
randomized controlled trial
stent comparison
target lesion failure
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
21
02
2022
received:
02
12
2021
accepted:
18
03
2022
pubmed:
7
4
2022
medline:
10
6
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
To compare the efficacy and safety of the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study. The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with DM when compared to patients without DM. Thus, whether the results from the SORT OUT X study apply to patients with and without DM remains unknown. In total 3146 patients were randomized to stent implantation with DTS (n = 1578; DM: n = 279) or SES (n = 1568; DM: n = 271). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year. At 1 year, the rate of TLF was increased in the DTS group compared to the SES group, both among patients with DM (9.3% vs. 4.8%; risk difference: 4.5%; incidence rate ratio: 1.99, 95% confidence interval [CI]: 1.02-3.90) and without DM (5.7% vs. 3.5%; incidence rate ratio: 1.67, 95% CI: 1.15-2.42). The differences were mainly explained by higher rates of TLR. Compared to the SES, the DTS was associated with an increased risk of TLF at 12 months in patients with and without DM. The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without DM.
Sections du résumé
OBJECTIVES
To compare the efficacy and safety of the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study.
BACKGROUND
The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with DM when compared to patients without DM. Thus, whether the results from the SORT OUT X study apply to patients with and without DM remains unknown.
METHODS
In total 3146 patients were randomized to stent implantation with DTS (n = 1578; DM: n = 279) or SES (n = 1568; DM: n = 271). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.
RESULTS
At 1 year, the rate of TLF was increased in the DTS group compared to the SES group, both among patients with DM (9.3% vs. 4.8%; risk difference: 4.5%; incidence rate ratio: 1.99, 95% confidence interval [CI]: 1.02-3.90) and without DM (5.7% vs. 3.5%; incidence rate ratio: 1.67, 95% CI: 1.15-2.42). The differences were mainly explained by higher rates of TLR.
CONCLUSION
Compared to the SES, the DTS was associated with an increased risk of TLF at 12 months in patients with and without DM. The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without DM.
Identifiants
pubmed: 35384254
doi: 10.1002/ccd.30175
pmc: PMC9542312
doi:
Substances chimiques
Antigens, CD34
0
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1965-1975Subventions
Organisme : OrbusNeich Medical, Fort Lauderdale, Florida, USA
Organisme : Biotronik, Bülach, Switzerland
Informations de copyright
© 2022 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.
Références
Am J Cardiol. 2016 Mar 1;117(5):735-42
pubmed: 26796194
Circulation. 2021 Jun;143(22):2155-2165
pubmed: 33823606
Stat Med. 1999 Mar 30;18(6):695-706
pubmed: 10204198
Am J Cardiol. 2019 Sep 1;124(5):671-677
pubmed: 31279405
JACC Cardiovasc Interv. 2013 Apr;6(4):334-43
pubmed: 23523459
J Am Coll Cardiol. 2021 Oct 12;78(15):1525-1537
pubmed: 34620410
Circ Cardiovasc Interv. 2016 Feb;9(2):e003255
pubmed: 26823484
Am Heart J. 2012 May;163(5):876-886.e2
pubmed: 22607867
Catheter Cardiovasc Interv. 2019 Mar 1;93(4):567-573
pubmed: 30244533
Circ Cardiovasc Interv. 2010 Jun 1;3(3):257-66
pubmed: 20442358
Am J Cardiol. 2012 Dec 1;110(11):1585-91
pubmed: 22959714
Catheter Cardiovasc Interv. 2022 Jun;99(7):1965-1975
pubmed: 35384254
Circ Cardiovasc Interv. 2016 Jul;9(7):
pubmed: 27412869
Am Heart J. 2018 Aug;202:49-53
pubmed: 29807307
Am J Cardiol. 2009 Feb 1;103(3):345-9
pubmed: 19166687
Am J Cardiol. 2011 Nov 1;108(9):1232-7
pubmed: 21864817
Eur Heart J. 2008 Nov;29(22):2733-41
pubmed: 18832385
Eur Heart J. 2007 Jul;28(14):1759-64
pubmed: 17540850
EuroIntervention. 2011 Jul;7(3):323-31
pubmed: 21729834
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
Circulation. 2020 Jun 23;141(25):2052-2063
pubmed: 32434381
JACC Cardiovasc Interv. 2019 Apr 8;12(7):624-633
pubmed: 30947936
Catheter Cardiovasc Interv. 2022 Feb;99(3):554-562
pubmed: 34390170
Eur Heart J. 2018 Jul 7;39(26):2460-2468
pubmed: 29931092
Lancet. 2015 Apr 18;385(9977):1527-35
pubmed: 25601789
Circ Cardiovasc Interv. 2015 Jun;8(6):
pubmed: 26043895
J Clin Epidemiol. 2004 Dec;57(12):1288-94
pubmed: 15617955
JACC Cardiovasc Interv. 2017 Mar 13;10(5):489-499
pubmed: 28279316
Int J Cardiol. 2017 Jan 1;226:60-64
pubmed: 27788391